GlassScriptPhysician profile
Christopher M Osan
NPI 1427477413
$20,484.66
in general payments reported to CMS, 2019-2025
49 companies · $2,884 in 2025
The $2,884 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,037 · 2020: $1,713 · 2021: $3,047 · 2022: $3,816 · 2023: $3,047 · 2024: $2,939 · 2025: $2,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,870.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,831.00 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $2,151.03 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,760.46 | 2021-2025 | |
| Novo Nordisk INC | $1,393.04 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,272.89 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Lilly USA, LLC | $1,112.65 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $919.99 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $876.69 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $871.56 | 2019-2025 | Trintellix, Glassia |
| Insulet Corporation | $756.10 | 2021-2025 | Omnipod |
| Esperion Therapeutics, INC. | $710.04 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $649.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $525.69 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $500.75 | 2022-2025 | Caplyta |
| Allergan, INC. | $495.29 | 2019-2021 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $437.87 | 2019-2023 | |
| Astellas Pharma US INC | $317.07 | 2022-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $289.29 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $285.01 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $274.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.69 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $205.68 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $191.82 | 2019-2025 | Watchman Flx |
| Horizon Therapeutics Plc | $156.25 | 2020-2023 | Krystexxa |
| Abbott Laboratories | $142.82 | 2023-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $137.94 | 2022-2025 | Auvelity |
| Gilead Sciences, INC. | $133.05 | 2019-2021 | |
| Exact Sciences Corporation | $129.01 | 2023-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $78.69 | 2024-2025 | Qelbree, Tlando, Xyosted |
| Otsuka America Pharmaceutical, INC. | $72.17 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $67.33 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $62.08 | 2023-2025 | Horizant |
| Genentech USA, INC. | $53.58 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $43.13 | 2025 | Fanapt |
| Sanofi Pasteur INC. | $41.42 | 2023 | |
| Antares Pharma, INC. | $40.67 | 2025 | Xyosted |
| Exeltis, USA INC. | $37.26 | 2023-2024 | Slynd |
| Shield Therapeutics INC | $35.98 | 2022-2023 | Accrufer |
| Halozyme INC | $24.23 | 2023 | |
| Corcept Therapeutics | $23.92 | 2019 | |
| Dexcom, INC. | $19.20 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $19.06 | 2025 | |
| Coopersurgical, INC. | $18.19 | 2019 | |
| Circassia INC. | $18.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.74 | 2021 | |
| Amgen INC. | $15.50 | 2022 | |
| Philips North America LLC | $14.97 | 2024 | (Ck7) Extended Holter |
| Alkermes, INC. | $13.43 | 2024 | Aristada, Lybalvi |
| Tactile Systems Technology INC | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Osan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.